Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
501 studies found for:    "Anemia, Hemolytic, Congenital"
Show Display Options
Rank Status Study
1 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath  );   Drug: Sirolimus (Rapamune  )
2 Recruiting Pyruvate Kinase Deficiency Natural History Study
Conditions: Pyruvate Kinase Deficiency;   Congenital Non-Spherocytic Hemolytic Anemia
Intervention:
3 Terminated The Dallas Hereditary Spherocytosis Cohort Study
Condition: Hereditary Spherocytosis
Intervention:
4 Completed Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
Conditions: Sickle Cell Disease;   Vaso-occlusive Crisis;   Pain Crisis
Interventions: Drug: GMI-1070;   Drug: Placebo
5 Completed
Has Results
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Condition: Thalassemia
Intervention:
6 Recruiting Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
Conditions: Iron Overload;   Beta-Thalassemia
Intervention: Drug: SP-420
7 Completed Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia
Condition: Sickle Cell Anemia
Interventions: Drug: Hydroxyurea;   Drug: L-Arginine;   Drug: Sildenafil
8 Recruiting Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency
Conditions: G6PD Normal;   G6PD Deficient;   Healthy
Intervention: Drug: Regimens (Primaquine, Methylene blue)
9 Completed Combo Chelation Trial
Conditions: Thalassemia;   Iron Overload
Intervention: Drug: Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)
10 Unknown  Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Conditions: Thalassemia;   Iron Overload
Intervention: Drug: Amlodipine
11 Unknown  Exercise Capacity in Pediatric Sickle Cell Anemia
Condition: Sickle Cell Anemia
Intervention:
12 Terminated
Has Results
A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
Condition: Sickle Cell Disease
Interventions: Drug: Eptifibatide;   Drug: Placebo
13 Completed MR Imaging of Diffuse Myocardial Fibrosis in Transfusion-Dependent Anemias
Conditions: Thalassemia Major;   Chronic Blood Transfusion Related Iron Overload
Intervention:
14 Completed
Has Results
An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
Condition: Anemia, Sickle Cell
Intervention: Drug: Prasugrel
15 Recruiting Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias
Conditions: Iron Overload;   Sickle Cell Disease;   Other Anemias
Interventions: Drug: Deferiprone;   Drug: Deferoxamine
16 Recruiting Stem Cell Transplant for Hemoglobinopathy
Conditions: Sickle Cell Disease;   Thalassemia;   Severe Congenital Neutropenia;   Diamond-Blackfan Anemia;   Shwachman-Diamond Syndrome
Interventions: Drug: Busulfan, Fludarabine, ATG, TLI;   Drug: Busulfan, Cyclophosphamide, ATG, GCSF;   Drug: Campath, Fludarabine, Cyclophosphamide;   Radiation: Total Body Irradiation;   Procedure: Stem cell infusion
17 Completed Heart Disease in Sickle Cell Anemia
Conditions: Sickle Cell Anemia;   Pulmonary Hypertension
Intervention:
18 Recruiting A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
Condition: Beta-thalassemia Major
Intervention: Genetic: LentiGlobin® BB305 Drug Product
19 Completed Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
Conditions: β-thalassemia;   Transfusional Iron Overload
Intervention: Drug: Deferasirox
20 Active, not recruiting Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN #0601) (The SCURT Study)
Condition: Sickle Cell Disease
Intervention: Biological: Hematopoietic Stem Cell Transplantation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years